Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…Substantia nigra hyperechogenicity in Mexican patients with Parkinson’s disease
Objective: To determine the prevalence of increased echogenicity in the substantia nigra in patients diagnosed with idiopathic Parkinson's disease at the University Hospital "Dr. José…SOD1 aggregation: A pathological link between Parkinson’s disease and amyotrophic lateral sclerosis?
Objective: To characterize (1) a novel association between superoxide dismutase 1 (SOD1) aggregation and neuronal loss in the Parkinson's disease (PD) brain and (2) the…AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons
Objective: To characterize the effect of AMP-activated protein kinase (AMPK) on ATP-sensitive K+ (K-ATP) channels on substantia nigra compacta (SNC) dopamine neurons in slices of…Astroglia exert a neuro-protective role in Parkinson’s disease by reducing oxygen stress through dopamine-induced activation of the pentose-phosphate pathway
Objective: Although dopaminergic neurons themselves take up most of the released dopamine (DA), a part of the DA appears to be taken up by astroglia.…Engrailed enhances dopamine synthesis in healthy dopaminergic neurons
Objective: The aim of the present study was to further elucidate the role of Engrailed in dopamine neurotransmission. Background: Engrailed1 and Engrailed2, collectively Engrailed, are…Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease
Objective: To assess if a microglial modulator, Glatiramer Acetate (GA), can restore loss of striatal dopamine (DA) and behavioral deficits following progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP)…Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease
Objective: Non-dopaminergic protein drug targets are of high interest to develop adjuvant treatments for currently insufficiently addressed symptoms of PD. RGS4, a regulator of G-protein…Vagus nerve stimulation as a novel treatment strategy for Parkinson’s disease
Objective: To assess the therapeutic potential of chronic vagus nerve stimulation (VNS) to attenuate the behavioral and neuronal deficits observed in Parkinson's disease (PD) by…Diffusion tensor imaging biomarkers of nigrostriatal neurodegeneration in early Parkinson’s disease
Objective: Identify magnetic resonance imaging (MRI) biomarkers of nigrostriatal neurodegeneration in early-stage drug-naïve Parkinson's disease (PD). Background: Diffusion tensor imaging (DTI) is an MRI technique…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »